Brodalumab治疗银屑病临床试验中的精神科不良事件分析
该分析基于安慰剂对照II期试验及其开放扩展、三项III期随机双盲对照试验(AMAGINE-1/2/3)及开放扩展,纳入4464例中重度银屑病患者,brodalumab暴露9161.8患者年。52周对照期内brodalumab组与ustekinumab组自杀意念和行为事件随访时间调整发生率相当(0.20 vs 0.60/100患者年),brodalumab组报告4例完成自杀,均有潜在精神疾病或应激因素。与对照比较及事件发生时间不支持brodalumab与自杀意念和行为存在因果关系。
要点
- 52周对照期内brodalumab与ustekinumab的自杀意念和行为发生率相当。
- brodalumab组4例完成自杀患者均存在潜在精神疾病或应激因素。
- 事件发生时间与对照比较不支持brodalumab导致自杀意念和行为。
核心结论
- 与对照比较及事件发生时间不支持brodalumab治疗与自杀意念和行为存在因果关系。
研究设计与样本
- 分析包含一项安慰剂对照II期试验及其开放长期扩展、三项III期随机双盲对照试验(AMAGINE-1、AMAGINE-2、AMAGINE-3)及其开放长期扩展。
- 纳入中重度银屑病患者4464例,brodalumab暴露9161.8患者年。
主要发现
- 52周对照期内brodalumab组与ustekinumab组自杀意念和行为事件随访时间调整发生率分别为0.20 vs 0.60/100患者年。
- brodalumab组报告4例完成自杀,其中1例 later adjudicated as indeterminate,所有患者均有潜在精神疾病或应激因素。
局限性
- 第52周后无对照臂。
- 对照研究期把握度不足以检测自杀等罕见事件的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with psoriasis are at increased risk for psychiatric comorbidities, including suicidal ideation and behavior (SIB). OBJECTIVE: To distinguish between the underlying risk and potential for treatment-induced psychiatric adverse events in patients with psoriasis being treated with brodalumab, a fully human anti-interleukin 17 receptor A monoclonal antibody. METHODS: Data were evaluated from a placebo-controlled, phase 2 clinical trial; the open-label, long-term extension of the phase 2 clinical trial; and three phase 3, randomized, double-blind, controlled clinical trials (AMAGINE-1, AMAGINE-2, and AMAGINE-3) and their open-label, long-term extensions of patients with moderate-to-severe psoriasis. RESULTS: The analysis included 4464 patients with 9161.8 patient-years of brodalumab exposure. The follow-up time-adjusted incidence rates of SIB events were comparable between the brodalumab and ustekinumab groups throughout the 52-week controlled phases (0.20 vs 0.60 per 100 patient-years). In the brodalumab group, 4 completed suicides were reported, 1 of which was later adjudicated as indeterminate; all patients had underlying psychiatric disorders or stressors. LIMITATIONS: There was no comparator arm past week 52. Controlled study periods were not powered to detect differences in rare events such as suicide. CONCLUSIONS: Comparison with controls and the timing of events do not indicate a causal relationship between SIB and brodalumab treatment.
引用
- Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol. 2017. PMID: 28985956. doi:10.1016/j.jaad.2017.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。